Wang J - Search Results

1

Hu X, Xu L, Chen K, Huang Y, Zhou D, Sun Y, Wang J, Yang J. Hu X, et al. Among authors: wang j. Zhonghua Xue Ye Xue Za Zhi. 2015 May;36(5):441-4. doi: 10.3760/cma.j.issn.0253-2727.2015.05.021. Zhonghua Xue Ye Xue Za Zhi. 2015. PMID: 26031538 Free PMC article. Chinese. No abstract available.

2

[Study on in vitro killing activity of DAAO/D-Ala system to K562e cells].

Wang J, Zhai Y, Zhang Y, Zhou H, Han F. Wang J, et al. Zhonghua Xue Ye Xue Za Zhi. 2002 Jan;23(1):12-5. Zhonghua Xue Ye Xue Za Zhi. 2002. PMID: 12015081 Chinese.

3

[Study on tumorigenic mechanism of human leukemia cell line in nude mice].

Xu X, Lu S, Ju X, Chen L, Wang J. Xu X, et al. Among authors: wang j. Zhonghua Xue Ye Xue Za Zhi. 2002 May;23(5):258-60. Zhonghua Xue Ye Xue Za Zhi. 2002. PMID: 12133449 Chinese.

4

[Study on the in vivo killing activity of YCD/5-FC gene therapy system on K562B cells].

Zhang Y, Wang J, Zhou H, Zhai Y. Zhang Y, et al. Among authors: wang j. Zhonghua Xue Ye Xue Za Zhi. 2002 Apr;23(4):173-5. Zhonghua Xue Ye Xue Za Zhi. 2002. PMID: 12133450 Chinese.

5

Clinical and molecular cytogenetic characteristics of dic(9;20) in adult acute lymphoblastic leukemia: a case report of three patients.

Song X, Gong S, Yang J, Wang J. Song X, et al. Among authors: wang j. Ann Hematol. 2007 May;86(5):347-51. doi: 10.1007/s00277-007-0255-0. Epub 2007 Jan 24. Ann Hematol. 2007. PMID: 17245591

6

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.

Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J. Lü S, et al. Among authors: wang j. J Pharmacol Exp Ther. 2008 Aug;326(2):423-31. doi: 10.1124/jpet.108.138131. Epub 2008 May 23. J Pharmacol Exp Ther. 2008. PMID: 18502982

7

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.

Lü S, Chen Z, Yang J, Chen L, Gong S, Zhou H, Guo L, Wang J. Lü S, et al. Among authors: wang j. Exp Hematol. 2008 Oct;36(10):1278-84. doi: 10.1016/j.exphem.2008.04.013. Epub 2008 Jun 17. Exp Hematol. 2008. PMID: 18562081 Free article.

8

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.

Lü S, Wang J, Xu X, Ni X, Huang C, Qiu H, Hu X, Yang J. Lü S, et al. Among authors: wang j. Int J Hematol. 2009 Jan;89(1):34-38. doi: 10.1007/s12185-008-0218-9. Epub 2008 Dec 13. Int J Hematol. 2009. PMID: 19082817 Clinical Trial.

9

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.

Lü S, Yang J, Chen Z, Gong S, Zhou H, Xu X, Wang J. Lü S, et al. Among authors: wang j. Exp Hematol. 2009 Jul;37(7):831-7. doi: 10.1016/j.exphem.2009.04.001. Epub 2009 May 6. Exp Hematol. 2009. PMID: 19426847 Free article.

10

A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.

Wang J, Lü S, Yang J, Song X, Chen L, Huang C, Hou J, Zhang W. Wang J, et al. J Hematol Oncol. 2009 Jul 30;2:32. doi: 10.1186/1756-8722-2-32. J Hematol Oncol. 2009. PMID: 19642997 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

218,871 results

Search Page

Filters